SE0100566D0 - Compounds - Google Patents
CompoundsInfo
- Publication number
- SE0100566D0 SE0100566D0 SE0100566A SE0100566A SE0100566D0 SE 0100566 D0 SE0100566 D0 SE 0100566D0 SE 0100566 A SE0100566 A SE 0100566A SE 0100566 A SE0100566 A SE 0100566A SE 0100566 D0 SE0100566 D0 SE 0100566D0
- Authority
- SE
- Sweden
- Prior art keywords
- compounds
- compound
- relates
- present
- gnrh
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0100566A SE0100566D0 (sv) | 2001-02-20 | 2001-02-20 | Compounds |
| EP02712084A EP1363903B1 (fr) | 2001-02-20 | 2002-02-15 | Derives indole et leur utilisation en tant qu'antagonistes de gnrh |
| PCT/GB2002/000679 WO2002066459A1 (fr) | 2001-02-20 | 2002-02-15 | Derives indole et leur utilisation en tant qu'antagonistes de gnrh |
| DE60215313T DE60215313T2 (de) | 2001-02-20 | 2002-02-15 | Indolderivate und deren verwendung als gnrh antagonisten |
| ES02712084T ES2274009T3 (es) | 2001-02-20 | 2002-02-15 | Derivados de indol y su uso como antagonistas de gnrh. |
| JP2002565974A JP4175893B2 (ja) | 2001-02-20 | 2002-02-15 | インドール誘導体とＧｎＲＨアンタゴニストとしてのその使用 |
| AT02712084T ATE342264T1 (de) | 2001-02-20 | 2002-02-15 | Indolderivate und deren verwendung als gnrh antagonisten |
| US10/227,193 US6809098B2 (en) | 2001-02-20 | 2002-08-21 | Compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0100566A SE0100566D0 (sv) | 2001-02-20 | 2001-02-20 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0100566D0 true SE0100566D0 (sv) | 2001-02-20 |
Family
ID=20283056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0100566A SE0100566D0 (sv) | 2001-02-20 | 2001-02-20 | Compounds |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6809098B2 (fr) |
| EP (1) | EP1363903B1 (fr) |
| JP (1) | JP4175893B2 (fr) |
| AT (1) | ATE342264T1 (fr) |
| DE (1) | DE60215313T2 (fr) |
| ES (1) | ES2274009T3 (fr) |
| SE (1) | SE0100566D0 (fr) |
| WO (1) | WO2002066459A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0022670D0 (en) | 2000-09-15 | 2000-11-01 | Astrazeneca Ab | Molecules |
| SE0101692D0 (sv) | 2001-05-14 | 2001-05-14 | Astrazeneca Ab | Compounds |
| US7253290B2 (en) | 2002-08-21 | 2007-08-07 | Astrazeneca Ab | Pyrazole derivatives as GnRH inhibitors |
| DE60318716T2 (de) | 2002-08-21 | 2009-01-08 | Astrazeneca Ab | Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren |
| TW200413351A (en) | 2002-08-21 | 2004-08-01 | Astrazeneca Ab | Chemical compounds |
| GB0219472D0 (en) | 2002-08-21 | 2002-10-02 | Astrazeneca Ab | Chemical compounds |
| TW200407127A (en) | 2002-08-21 | 2004-05-16 | Astrazeneca Ab | Chemical compounds |
| EP1620091B1 (fr) | 2003-05-05 | 2010-03-31 | Probiodrug AG | Inhibiteurs de glutaminyl-cyclase |
| KR20100038477A (ko) | 2003-05-05 | 2010-04-14 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
| EP1660091B1 (fr) | 2003-07-07 | 2009-04-15 | Neurocrine Biosciences, Inc. | Derives de pyrimidine-2,4-dione, servant d antagonistes au recepteur de l hormone de liberation de la gonadotropine |
| WO2005007633A1 (fr) | 2003-07-07 | 2005-01-27 | Neurocrine Biosciences, Inc. | Antagonistes des recepteurs des hormones liberant des gonadotropines et procedes connexes |
| EP1646389B1 (fr) | 2003-07-07 | 2008-09-10 | Neurocrine Biosciences, Inc. | Derives de pyrimidine-2, 4-dione utilises comme antagonistes du recepteur d'hormone liberant de la gonadotrophine |
| GB0320806D0 (en) | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Therapeutic treatment |
| CN1867324A (zh) | 2003-10-15 | 2006-11-22 | 前体生物药物股份公司 | 谷氨酰胺酰基环化酶效应物和谷氨酸环化酶效应物的应用 |
| DK1713780T3 (da) * | 2004-02-05 | 2012-05-07 | Probiodrug Ag | Hidtil ukendte inhibitorer af glutaminylcyklase |
| CA2554809C (fr) * | 2004-02-05 | 2014-04-29 | Probiodrug Ag | Nouveaux inhibiteurs de la glutaminyl-cyclase comportant de la n thiouree alkyle et de l'imidazolyl substitue par thioamide |
| TW201130854A (en) | 2009-12-22 | 2011-09-16 | Bayer Schering Pharma Ag | Pyridinone derivatives and pharmaceutical compositions thereof |
| WO2012175514A1 (fr) | 2011-06-21 | 2012-12-27 | Bayer Intellectual Property Gmbh | Dérivés de pyridinone et compositions pharmaceutiques les contenant |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2240108A1 (fr) | 1995-12-14 | 1997-06-19 | Peter Lin | Antagonistes de l'hormone de liberation de la gonadotropine |
| AU709090B2 (en) * | 1995-12-14 | 1999-08-19 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| AU704937B2 (en) * | 1995-12-14 | 1999-05-06 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6200957B1 (en) | 1995-12-14 | 2001-03-13 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| EA000828B1 (ru) | 1995-12-14 | 2000-04-24 | Мерк Энд Ко., Инк. | Антагонисты гонадотропин-высвобождающего фактора |
| CA2292880A1 (fr) | 1997-06-05 | 1998-12-10 | Merck & Co., Inc. | Antagonistes de l'hormone de liberation de la gonadotrophine |
| CA2291647A1 (fr) | 1997-06-05 | 1998-12-10 | Merck & Co., Inc. | Antagonistes de la gonadoliberine |
| EP0986385A4 (fr) | 1997-06-05 | 2001-05-16 | Merck & Co Inc | Antagonistes de gonadoliberine |
| US6156772A (en) | 1997-06-05 | 2000-12-05 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| CA2292605A1 (fr) | 1997-06-05 | 1998-12-10 | Merck & Co., Inc. | Antagonistes de l'hormone de liberation des gonadotrophines |
| JP2002503252A (ja) | 1997-06-05 | 2002-01-29 | メルク エンド カンパニー インコーポレーテッド | ゴナドトロピン放出ホルモンの拮抗薬 |
| AU1124399A (en) | 1997-10-28 | 1999-05-17 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| WO1999021557A1 (fr) | 1997-10-28 | 1999-05-06 | Merck & Co., Inc. | Antagonistes de la gonadoliberine |
| JP2002503661A (ja) | 1998-02-11 | 2002-02-05 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬 |
| JP2002503660A (ja) | 1998-02-11 | 2002-02-05 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬 |
| AU3118399A (en) | 1998-04-02 | 1999-10-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| WO1999051595A1 (fr) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonistes de l'hormone liberant la gonadotropine (gnrh) |
| JP2002510631A (ja) | 1998-04-02 | 2002-04-09 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬 |
| JP2002510630A (ja) | 1998-04-02 | 2002-04-09 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬 |
| CA2326140A1 (fr) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonistes de l'hormone liberant la gonadotropine (gnrh) |
| AU3117899A (en) | 1998-04-02 | 1999-10-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| WO2000053185A1 (fr) | 1999-03-10 | 2000-09-14 | Merck & Co., Inc. | Composes 6-azaindole utilises comme antagonistes d'une hormone liberant la gonadotropine |
| JP2002538206A (ja) | 1999-03-10 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物 |
| EP1161431A4 (fr) | 1999-03-10 | 2002-04-24 | Merck & Co Inc | Composes 6-azaindole utilises comme antagonistes d'une hormone liberant la gonadotropine |
| JP2002538204A (ja) | 1999-03-10 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物 |
| WO2000053180A1 (fr) | 1999-03-10 | 2000-09-14 | Merck & Co., Inc. | Composes de 6-azaindole antagonistes de la gonadoliberine |
| JP2003526618A (ja) | 1999-03-10 | 2003-09-09 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物 |
-
2001
- 2001-02-20 SE SE0100566A patent/SE0100566D0/xx unknown
-
2002
- 2002-02-15 JP JP2002565974A patent/JP4175893B2/ja not_active Expired - Fee Related
- 2002-02-15 AT AT02712084T patent/ATE342264T1/de not_active IP Right Cessation
- 2002-02-15 ES ES02712084T patent/ES2274009T3/es not_active Expired - Lifetime
- 2002-02-15 EP EP02712084A patent/EP1363903B1/fr not_active Expired - Lifetime
- 2002-02-15 WO PCT/GB2002/000679 patent/WO2002066459A1/fr not_active Ceased
- 2002-02-15 DE DE60215313T patent/DE60215313T2/de not_active Expired - Fee Related
- 2002-08-21 US US10/227,193 patent/US6809098B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1363903A1 (fr) | 2003-11-26 |
| JP2004521914A (ja) | 2004-07-22 |
| WO2002066459A1 (fr) | 2002-08-29 |
| ATE342264T1 (de) | 2006-11-15 |
| JP4175893B2 (ja) | 2008-11-05 |
| DE60215313T2 (de) | 2007-06-14 |
| US20030171354A1 (en) | 2003-09-11 |
| ES2274009T3 (es) | 2007-05-16 |
| EP1363903B1 (fr) | 2006-10-11 |
| DE60215313D1 (de) | 2006-11-23 |
| US6809098B2 (en) | 2004-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0100568D0 (sv) | Compounds | |
| SE0100567D0 (sv) | Compounds | |
| SE0100566D0 (sv) | Compounds | |
| DK1317419T3 (da) | Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler | |
| DE60234577D1 (de) | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält | |
| MXPA04005209A (es) | Antagonistas del receptor de adenosina a2a. | |
| BR0012450A (pt) | Benzimidazóis substituìdos | |
| BG106095A (bg) | Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици | |
| GB0112348D0 (en) | Compounds | |
| MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
| SE0100569D0 (sv) | New compounds | |
| TNSN04203A1 (en) | Benzoxazinone-derived compounds, their preparation and use as medicaments | |
| GB0222514D0 (en) | Organic compounds | |
| DK1458393T3 (da) | Substituerede diketopiperaziner som oxytocinantagonister | |
| SE0102440D0 (sv) | New compound | |
| DE60124144D1 (de) | Pharmazeutische zusammenstellungen zur verstärkung der artzneimitteleffekte | |
| SE0101692D0 (sv) | Compounds | |
| GB2446341A (en) | Method and system for transdermal drug delivery | |
| ATE384066T1 (de) | Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren | |
| MXPA02008870A (es) | Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos. | |
| DE60114597D1 (de) | Naphthamid-neurokinin antagonisten zur verwendung als medikamente | |
| SE0004827D0 (sv) | Therapeutic compounds | |
| TW200634002A (en) | Chemical compounds | |
| ATE301997T1 (de) | Antivirale therapie | |
| ATE270886T1 (de) | Antivirale therapie |